ORION OYJ |
Market Closed -
Other stock markets
|
After market 03:29:15 pm | |||
| 37.6 EUR | +0.13% |
|
37.34 | -0.69% |
| May. 07 | Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025 | CI |
| Apr. 26 | Orion Corporation Announces Appointments to Nomination Committee | CI |
| Sales 2024 * | 1.38B 1.49B | Sales 2025 * | 1.45B 1.57B | Capitalization | 5.29B 5.73B |
|---|---|---|---|---|---|
| Net income 2024 * | 242M 262M | Net income 2025 * | 250M 271M | EV / Sales 2024 * | 3.81 x |
| Net cash position 2024 * | 46.22M 50.09M | Net cash position 2025 * | 3.2M 3.46M | EV / Sales 2025 * | 3.64 x |
| P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
21.1
x | Employees | 3,698 |
| Yield 2024 * |
4.46% | Yield 2025 * |
4.55% | Free-Float | 88.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Orion Oyj
More press releases
More news
| 1 day | +0.16% | ||
| 1 week | -0.58% | ||
| Current month | +4.75% | ||
| 1 month | +13.19% | ||
| 3 months | -2.62% | ||
| 6 months | +1.05% | ||
| Current year | -4.53% |
1 week
37.12
38.20
1 month
32.2538.20
Current year
31.8645.29
1 year
31.8645.29
3 years
31.8655.16
5 years
28.7655.16
10 years
22.5758.50
| Managers | Title | Age | Since |
|---|---|---|---|
Liisa Hurme
CEO | Chief Executive Officer | 57 | 98-12-31 |
| Chief Operating Officer | - | 15-12-31 | |
Outi Vaarala
CTO | Chief Tech/Sci/R&D Officer | 62 | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 63 | 21-03-24 | |
| Director/Board Member | 61 | 17-03-21 | |
| Director/Board Member | 54 | 22-03-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.96% | 664 M€ | +10.28% | ||
| 2.87% | 473 M€ | +6.93% | ||
| 0.35% | 1,083 M€ | +4.05% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 37.6 | +0.13% | 91 357 |
| 24-05-22 | 37.55 | +0.67% | 119,070 |
| 24-05-21 | 37.3 | -1.19% | 226,804 |
| 24-05-20 | 37.75 | +0.16% | 106,087 |
| 24-05-17 | 37.69 | -0.05% | 193,119 |
Delayed Quote Nasdaq Helsinki, May 23, 2024 at 10:08 am EDT
More quotes
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
37.55
EUR
Average target price
39
EUR
Spread / Average Target
+3.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.53% | 5.73B | |
| +37.93% | 723B | |
| +34.36% | 595B | |
| -2.78% | 369B | |
| +20.57% | 332B | |
| +2.39% | 282B | |
| +17.26% | 244B | |
| +9.60% | 208B | |
| -4.58% | 205B | |
| +0.16% | 168B |
- Stock Market
- Equities
- ORNBV Stock
